Back to News
Market Impact: 0.15
Cardiff Oncology Appoints Leila Alland as Interim Chief Medical Officer and Increases Authorized Shares to 300,000,000
Source: Nasdaq
Management & Governance
Cardiff Oncology said Chief Medical Officer Dr. Roger Sidhu separated from the company on October 22, 2026, as part of a mutually agreed transition. The next day, the company entered into an amended and restated consulting agreement with Lei; the available article text does not provide further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- FedEx beats expectations, raises outlook in first report since calendar adjustment
- Warsh says politics played no role in Fed’s rate decision by group he is ’honored’ to lead
- Tencent’s Cloud Boss Plays Long Game to Patch ‘Leaky’ AI Ship
- Microsoft reveals strong cloud growth amid financial reporting overhaul
- ECB to hold rates as investors focus on French bonds, Lagarde’s future
- Q2 Holdings reports Q3 revenue of $225.8M, raises guidance